ZDA
SGTX

Zweig-DiMenna Associates’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Zweig-DiMenna Associates’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-9,116
Closed -$1.27M – 207
2021
Q2 		$1.27M Buy
9,116
+1,178
+15% +$207K 0.08% 161
2021
Q1 		$2.31M Buy
7,938
+7,461
+1,564% +$2.97M 0.16% 118
2020
Q4 		$298K Buy
+477
New +$216K 0.02% 135

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Zweig-DiMenna Associates's SGTX Position: Q3 2021 in Review

Zweig-DiMenna Associates sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2021, closing a stake of 9,116 shares — an estimated $1.27M sold.

Zweig-DiMenna Associates first reported a position in SGTX in Q4 2020 and held it in 3 quarters. The position peaked at $2.31M in Q1 2021. 45 funds tracked by Wall St. Rank hold SGTX as of Q3 2021.

  • Zweig-DiMenna Associates reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 9,116 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $1.27M.
  • Zweig-DiMenna Associates first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Zweig-DiMenna Associates's Sigilon Therapeutics, Inc. Common Stock position peaked at $2.31M in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2021, filed 25 Oct 2021.